Up-regulation of S100P predicts the poor long-term survival and construction of prognostic signature for survival and immunotherapy in patients with pancreatic cancer

References

• Mizrahi JD, Surana R, Valle JW, et al. Pancreatic cancer. Lancet. 2020;395(10242):2008–2020.
   PubMed Web of Science ®Google Scholar
• Liu R, Wakabayashi G, Palanivelu C, et al. International consensus statement on robotic pancreatic surgery. Hepatobiliary Surg Nutr. 2019;8(4):345–360.
   PubMed Web of Science ®Google Scholar
• Suker M, Beumer BR, Sadot E, et al. FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis. Lancet Oncol. 2016;17(6):801–810.
   PubMed Web of Science ®Google Scholar
• Zeng S, Pöttler M, Lan B, et al. Chemoresistance in pancreatic cancer. Int J Mol Sci. 2019;20:4504.
   Web of Science ®Google Scholar
• Morrison AH, Byrne KT, Vonderheide RH. Immunotherapy and prevention of pancreatic cancer. Trends Cancer. 2018;4(6):418–428.
   PubMed Web of Science ®Google Scholar
• Feng M, Xiong G, Cao Z, et al. PD-1/PD-L1 and immunotherapy for pancreatic cancer. Cancer Lett. 2017;407:57–65.
   PubMed Web of Science ®Google Scholar
• Raj N, Zheng Y, Kelly V, et al. PD-1 blockade in advanced adrenocortical carcinoma. J Clin Oncol. 2020;38(1):71–80.
   PubMed Web of Science ®Google Scholar
• Akin Telli T, Bregni G, Camera S, et al. PD-1 and PD-L1 inhibitors in oesophago-gastric cancers. Cancer Lett. 2020;469:142–150.
   PubMed Web of Science ®Google Scholar
• Huang R, Mao M, Lu Y, et al. A novel immune-related genes prognosis biomarker for melanoma: associated with tumor microenvironment. Aging (Albany NY). 2020;12(8):6966–6980.
   PubMedGoogle Scholar
• Li J, Byrne KT, Yan F, et al. Tumor cell-intrinsic factors underlie heterogeneity of immune cell infiltration and response to immunotherapy. Immunity. 2018;49(1):178–93.e7.
   PubMed Web of Science ®Google Scholar
• Wang WQ, Liu L, Xu HX, et al. Infiltrating immune cells and gene mutations in pancreatic ductal adenocarcinoma. Br J Surg. 2016;103(9):1189–1199.
   PubMed Web of Science ®Google Scholar
• Liu T, Wu H, Qi J, et al. Seven immune-related genes prognostic power and correlation with tumor-infiltrating immune cells in hepatocellular carcinoma. Cancer Med. 2020;9(20):7440-7452.
   Web of Science ®Google Scholar
• Cao J, Yang X, Li J, et al. Screening and identifying immune-related cells and genes in the tumor microenvironment of bladder urothelial carcinoma: based on TCGA database and bioinformatics. Front Oncol. 2019;9:1533.
   PubMed Web of Science ®Google Scholar
• Zhang M, Zhu K, Pu H, et al. An immune-related signature predicts survival in patients with lung adenocarcinoma. Front Oncol. 2019;9:1314.
   PubMed Web of Science ®Google Scholar
• Wu G, Deng Z, Jin Z, et al. Identification of prognostic immune-related genes in pancreatic adenocarcinoma and establishment of a prognostic nomogram: a bioinformatic study. Biomed Res Int. 2020;2020:1346045.
   PubMed Web of Science ®Google Scholar
• Wang W, Yan L, Guan X, et al. Identification of an immune-related signature for predicting prognosis in patients with pancreatic ductal adenocarcinoma. Front Oncol. 2020;10:618215.
   PubMed Web of Science ®Google Scholar
• Zhang C, Zou Y, Zhu Y, et al. Three immune-related prognostic mRNAs as therapeutic targets for pancreatic cancer. Front Med (Lausanne). 2021;8:649326.
   PubMed Web of Science ®Google Scholar
• Chen B, Hu C, Jiang L, et al. Exploring the significance of novel immune-related gene signatures in the prognosis and immune features of pancreatic adenocarcinoma. Int Immunopharmacol. 2021;92:107359.
   PubMed Web of Science ®Google Scholar
• Bhattacharya S, Andorf S, Gomes L, et al. ImmPort: disseminating data to the public for the future of immunology. Immunol Res. 2014;58(2–3):234–239.
   PubMed Web of Science ®Google Scholar
• Ritchie ME, Phipson B, Wu D, et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015;43(7):e47.
   PubMed Web of Science ®Google Scholar
• Yu G, Wang LG, Han Y, et al. clusterProfiler: an R package for comparing biological themes among gene clusters. OMICS. 2012;16(5):284–287.
   PubMed Web of Science ®Google Scholar
• Walter W, Sánchez-Cabo F, Ricote M. GOplot: an R package for visually combining expression data with functional analysis. Bioinformatics. 2015;31(17):2912–2914.
   PubMed Web of Science ®Google Scholar
• von Mering C, Huynen M, Jaeggi D, et al. STRING: a database of predicted functional associations between proteins. Nucleic Acids Res. 2003;31(1):258–261.
   PubMed Web of Science ®Google Scholar
• Friedman J, Hastie T, Tibshirani R. Regularization paths for generalized linear models via coordinate descent. J Stat Softw. 2010;33(1):1–22.
   PubMed Web of Science ®Google Scholar
• Subramanian A, Tamayo P, Mootha VK, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005;102(43):15545–15550.
   PubMed Web of Science ®Google Scholar
• Mei S, Meyer CA, Zheng R, et al. Cistrome cancer: a web resource for integrative gene regulation modeling in cancer. Cancer Res. 2017;77(21):e19–e22.
   PubMed Web of Science ®Google Scholar
• Ru B, Wong CN, Tong Y, et al. TISIDB: an integrated repository portal for tumor-immune system interactions. Bioinformatics. 2019;35(20):4200–4202.
   PubMed Web of Science ®Google Scholar
• Tang Z, Li C, Kang B, et al. GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res. 2017;45(W1):W98–w102.
   PubMed Web of Science ®Google Scholar
• Li T, Fan J, Wang B, et al. TIMER: a web server for comprehensive analysis of tumor-infiltrating immune cells. Cancer Res. 2017;77(21):e108–e10.
   PubMed Web of Science ®Google Scholar
• Newman AM, Liu CL, Green MR, et al. Robust enumeration of cell subsets from tissue expression profiles. Nat Methods. 2015;12(5):453–457.
   PubMed Web of Science ®Google Scholar
• Geeleher P, Cox N, Huang RS. pRRophetic: an R package for prediction of clinical chemotherapeutic response from tumor gene expression levels. PloS One. 2014;9(9):e107468.
   PubMed Web of Science ®Google Scholar
• Ren B, Cui M, Yang G, et al. Tumor microenvironment participates in metastasis of pancreatic cancer. Mol Cancer. 2018;17(1):108.
   PubMedGoogle Scholar
• Lee PY, Schulert GS, Canna SW, et al. Adenosine deaminase 2 as a biomarker of macrophage activation syndrome in systemic juvenile idiopathic arthritis. Ann Rheum Dis. 2020;79(2):225–231.
   PubMed Web of Science ®Google Scholar
• Zavialov AV, Gracia E, Glaichenhaus N, et al. Human adenosine deaminase 2 induces differentiation of monocytes into macrophages and stimulates proliferation of T helper cells and macrophages. J Leukoc Biol. 2010;88(2):279–290.
   PubMed Web of Science ®Google Scholar
• Liu J, Jiang M, Ma Z, et al. TLR1/2 ligand–stimulated mouse liver endothelial cells secrete IL-12 and trigger CD8+T cell immunity in vitro. J Immunol. 2013;191(12):6178–6190.
   PubMed Web of Science ®Google Scholar
• Lu CC, Kuo HC, Wang FS, et al. Upregulation of TLRs and IL-6 as a marker in human colorectal cancer. Int J Mol Sci. 2014;16(1):159–177.
   PubMed Web of Science ®Google Scholar
• Zahm CD, Colluru VT, McIlwain SJ, et al. TLR stimulation during T-cell activation lowers PD-1 expression on CD8+T cells. Cancer Immunol Res. 2018;6(11):1364–1374.
   PubMed Web of Science ®Google Scholar
• Wang Y, Su L, Morin MD, et al. Adjuvant effect of the novel TLR1/TLR2 agonist diprovocim synergizes with anti-PD-L1 to eliminate melanoma in mice. Proc Natl Acad Sci U S A. 2018;115(37):E8698–E706.
   PubMed Web of Science ®Google Scholar
• Penafuerte C, Perez-Quintero LA, Vinette V, et al. Mining the complex family of protein tyrosine phosphatases for checkpoint regulators in immunity. Curr Top Microbiol Immunol. 2017;410:191–214.
   PubMed Web of Science ®Google Scholar
• Kang X, Kim J, Deng M, et al. Inhibitory leukocyte immunoglobulin-like receptors: immune checkpoint proteins and tumor sustaining factors. Cell Cycle. 2016;15(1):25–40.
   PubMed Web of Science ®Google Scholar
• Douziech N, Calvo E, Coulombe Z, et al. Inhibitory and stimulatory effects of somatostatin on two human pancreatic cancer cell lines: a primary role for tyrosine phosphatase SHP-11. Endocrinology. 1999;140(2):765–777.
   PubMed Web of Science ®Google Scholar
• Arumugam T, Simeone DM, Van Golen K, et al. S100P promotes pancreatic cancer growth, survival, and invasion. Clin Cancer Res off J Am Assoc Cancer Res. 2005;11(15):5356–5364.
   PubMed Web of Science ®Google Scholar
• Ji YF, Huang H, Jiang F, et al. S100 family signaling network and related proteins in pancreatic cancer (Review). Int J Mol Med. 2014;33(4):769–776.
   PubMed Web of Science ®Google Scholar
• He P, Yang JW, Yang VW, et al. Kruppel-like factor 5, increased in pancreatic ductal adenocarcinoma, promotes proliferation, acinar-to-ductal metaplasia, pancreatic intraepithelial neoplasia, and tumor growth in mice. Gastroenterology. 2018;154(5):1494–508 e13.
   PubMed Web of Science ®Google Scholar
• Ma Y, Wang Q, Liu F, et al. KLF5 promotes the tumorigenesis and metastatic potential of thyroid cancer cells through the NF-kappaB signaling pathway. Oncol Rep. 2018;40:2608–2618.
   PubMed Web of Science ®Google Scholar
• Torphy RJ, Schulick RD, Zhu Y. Understanding the immune landscape and tumor microenvironment of pancreatic cancer to improve immunotherapy. Mol Carcinog. 2020;59(7):775–782.
   PubMed Web of Science ®Google Scholar
• Upadhrasta S, Zheng L. Strategies in developing immunotherapy for pancreatic cancer: recognizing and correcting multiple immune “defects” in the tumor microenvironment. J Clin Med. 2019;8(9):1472.
   Web of Science ®Google Scholar
• Ino Y, Yamazaki-Itoh R, Shimada K, et al. Immune cell infiltration as an indicator of the immune microenvironment of pancreatic cancer. Br J Cancer. 2013;108(4):914–923.
   PubMed Web of Science ®Google Scholar
• Tahkola K, Mecklin JP, Wirta EV, et al. High immune cell score predicts improved survival in pancreatic cancer. Virchows Arch. 2018;472(4):653–665.
   PubMed Web of Science ®Google Scholar
• Chan TA, Yarchoan M, Jaffee E, et al. Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic. Ann Oncol. 2019;30(1):44–56.
   PubMed Web of Science ®Google Scholar
• Ott PA, Bang YJ, Piha-Paul SA, et al. T-cell-inflamed gene-expression profile, programmed death ligand 1 expression, and tumor mutational burden predict efficacy in patients treated with pembrolizumab across 20 cancers: KEYNOTE-028. J Clin Oncol. 2019;37(4):318–327.
   PubMed Web of Science ®Google Scholar
• Wang C, Liang H, Lin C, et al. Molecular subtyping and prognostic assessment based on tumor mutation burden in patients with lung adenocarcinomas. Int J Mol Sci. 2019;20(17):4251.
   Web of Science ®Google Scholar
• Schrock AB, Ouyang C, Sandhu J, et al. Tumor mutational burden is predictive of response to immune checkpoint inhibitors in MSI-high metastatic colorectal cancer. Ann Oncol. 2019;30(7):1096–1103.
   PubMed Web of Science ®Google Scholar
• Johnson A, Severson E, Gay L, et al. Comprehensive genomic profiling of 282 pediatric low- and high-grade gliomas reveals genomic drivers, tumor mutational burden, and hypermutation signatures. Oncologist. 2017;22(12):1478–1490.
   PubMed Web of Science ®Google Scholar